Patterns of amino acid conservation have served as a tool for understanding protein evolution 1 . The same principles have also found broad application in human genomics, driven by the need to interpret the pathogenic potential of variants in patients 2 . Here we performed a systematic comparative genomics analysis of human disease-causing missense variants. We found that an appreciable fraction of disease-causing alleles are fixed in the genomes of other species, suggesting a role for genomic context. We developed a model of genetic interactions that predicts most of these to be simple pairwise compensations. Functional testing of this model on two known human disease genes 3, 4 revealed discrete cis amino acid residues that, although benign on their own, could rescue the human mutations in vivo. This approach was also applied to ab initio gene discovery to support the identification of a de novo disease driver in BTG2 that is subject to protective cis-modification in more than 50 species. Finally, on the basis of our data and models, we developed a computational tool to predict candidate residues subject to compensation. Taken together, our data highlight the importance of cis-genomic context as a contributor to protein evolution; they provide an insight into the complexity of allele effect on phenotype; and they are likely to assist methods for predicting allele pathogenicity 5, 6 . Understanding the nature and prevalence of genetic interactions has the potential to elucidate the evolutionary forces that act on protein residues, protein complexes and, more broadly, genomes. Some studies have reported that interactions are ubiquitous and contribute considerably to the evolutionary landscape 7, 8 , while others found that interactions are rare 9 . Even among those who agree that genetic interactions are important, the architecture of these interactions remains unclear: some studies find distinct interactions between two or three sites 10, 11 , while others propose a complex interaction network, effectively responding to aggregate properties of the entire protein or the entire genome 12, 13 . One practical utility of comparative genomics has been highlighted by our appreciation of the large number of rare variants in humans and the difficulty in inferring their contribution to disease 2 .
To prioritize variants of interest, frequency in control populations and evolutionary conservation have become two prominent filters. Conserved regions are considered more likely to be intolerant of variation 1 ; programs such as PolyPhen 5 and SIFT 6 have employed this principle to predict functional effects of variants 2 . Although useful, these strategies are constrained, in part because they do not take into consideration the genomic context of the mutated allele. An allele can appear damaging in one sequence yet be neutral in an orthologous sequence of another species. This phenomenon, referred to as compensated pathogenic deviation (CPD), contributes an unknown, but potentially large, number of false negatives to the evaluation of functional sites 14, 15 .
To examine the prevalence of CPDs, and to identify such sites, we used comparative genomics. A typical, non-CPD allele should cause the same phenotype in any orthologous sequence, regardless of genetic background. By contrast, when a variant that causes human genetic disease is found in a wild-type orthologous sequence, it is likely that the genetic background of that species exerts a compensatory effect on such a variant: it suppresses the phenotype, and thus protects the variant from negative selection 11, [14] [15] [16] . Previous studies have used this insight to quantify the fraction of CPD interspecies substitutions at ,10% (refs [14] [15] [16] . Other studies have reported estimates of the inverse value, namely the fraction of pathogenic variants that are present as CPDs in other species, ranging from 2-18% (refs 17, 18) . We set out to produce a new estimate of this value. We collected two data sets diagram showing sizes and overlap of the ClinVar and HumVar data sets, and how many are found in the multiple sequence alignment. b, Estimated number of human disease variants found in the alignment. The smallest estimate (3.0%, dark blue) comes from using the intersection of both variant data sets, requiring the variant to be absent from 6,503 human exomes, and filtering out alignments with low-quality scores. With any methodology, at least 88% of human disease variants (grey) are not found in the alignment. c, d, Potential mechanisms for the occurrence of CPDs in evolution. Branches where the variant is fixed are purple; branches where the variant is pathogenic are red. In c, the variant is present neutrally in an ancestor, but is lost in primates. Subsequent substitutions cause the ancestral allele to become pathogenic. In d, the variant is pathogenic in the ancestor, but mutations in a non-human branch cause it to become tolerated, and it arises later by mutation and becomes fixed.
of missense single-nucleotide variants (SNVs), annotated as either benign or pathogenic, derived from two databases, one based on the literature ('HumVar') 5, 19, 20 and one based on clinical genetic laboratories and investigator submissions ('ClinVar') 20 . Although the two databases are not fully independent, the majority of pathogenic variants were listed in one or the other (Fig. 1a) . Overall, these data sets comprised 69,905 human missense mutations across 13,040 genes. We compared this data set to orthologous proteins from 100 vertebrates. As expected, we found the mutant residue for a large number of likely neutral human variants to be fixed in orthologues. However, the number of pathogenic missense variants found in orthologues (CPDs) was surprisingly high: 5.6% 6 0.5% of ClinVar variants and 6.7% 6 0.4% of HumVar variants were found in the alignment of mammals. For all vertebrates, these numbers increase to 10.2% 6 0.7% and 12.0% 6 0.5%, respectively ( Table 1) .
Mindful of the possibility of false pathogenic annotations, we applied several filtering steps, including cross-referencing HumVar and ClinVar variant annotations with population frequency data, filtering on the basis of alignment quality 21 , using alternative alignment methodologies, and requiring variants to be present in multiple species (Table 1 and Supplementary Note). Some filters did remove bona fide recessive alleles (since we did not allow carriers), as well as disease variants with incomplete penetrance, even though this class of alleles is, by definition, sensitive to genomic context and thus likely to be affected by compensation 22 . Nevertheless, all filtering steps retained a substantial number of variants ( Supplementary Tables 1 and 2 ). Including only variants that pass all filtering steps and are detected in .1 vertebrate, we predict that the minimum estimate of CPDs in human patients is 3% (Fig. 1b) . This is consistent with previous analyses, which have found that stringent filtering does not change the observed properties of CPDs to any notable extent 16, 17 . As a final test, we extracted post hoc pathogenic alleles from three different sources, each of which used independent means for assessing pathogenicity in acute paediatric disorders; overall, CPD rates ranged once again between 3% and 9%; additional analyses of other possible sources of bias were likewise consistent with our initial observations and previous studies (see Supplementary Note and Supplementary Tables 3, 4, 5) .
We next turned to the question of the structure of the genetic interactions underlying such sites. Broadly, there are two possibilities: suppression of the disease phenotype may be the result of a small number of discrete compensatory substitutions; or suppression may be caused by a global shift in the properties of the gene, or the whole genome, caused by numerous substitutions that, individually, have small effects. The difference between these two models should be visible in the distribution of CPDs among orthologous sequences. During evolution, variants arise stochastically through a Poisson process: the expected amount of evolutionary time required to produce a given substitution is distributed exponentially 23 . For a CPD, the distribution should be different; the presence of a CPD mandates the presence of all compensatory substitutions necessary for the CPD to be rendered neutral. As such, the expected evolutionary time required to produce a CPD is the sum of the times required to produce each compensatory substitution, followed by the time required to produce the CPD.
Previous studies have proposed different processes by which CPDs arise. The most plausible option is a neutral mechanism, in which the compensatory substitutions are neutral and arise/fix neutrally before the pathogenic substitution appears (Fig. 1c, d and Fig. 2a ). In this case, the time required for each substitution to arise is given by an exponential distribution, and the time for all compensatory sites to arise is approximated by the convolution of multiple exponential distributions (a gamma distribution, in the case where all exponential distributions are identical). The number of exponential distributions included in the convolution corresponds to one plus the number of compensatory substitutions required, and it can be inferred from the shape of the distribution (Fig. 2b) .
Although the evolutionary time separating two sequences is not observable directly, we can approximate it using sequence distance (one minus sequence identity) 24 . We plotted the number of missense variants observed as a function of sequence distance for neutral variants and for CPDs. Qualitatively, the shapes of both distributions match theoretical expectations. The two distributions are distinct from each other (P 5 1.6 3 10
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, Kolmogorov-Smirnov two-sample test; Supplementary Tables 6, 7) . Additionally, the observed distribution of CPDs is weighted towards shorter evolutionary distances, as expected if most CPDs require a small number of individual compensatory substitutions, as opposed to the normal distribution expected if CPDs require many individual compensatory substitutions (Fig. 2b, d ).
To obtain a more precise estimate of the number of compensatory substitutions, we used maximum likelihood to fit several versions of the convolution-of-exponentials model with different combinations of variant data sets and alignment strategies ( Fig. 2c, d ; see Methods Tables 6, 7 ). Most versions of the model fit best as the convolution of approximately two exponential distributions, supporting a mechanism in which most CPDs are compensated by simple pairwise interactions. Additionally, most models reported similar rates of evolution for neutral variants, CPDs and compensatory variants, suggesting that the target size for compensatory changes is small. We repeated these analyses with multiple different variant data sets and alignment strategies, finding similar results each time (Extended Data Fig. 1 and Supplementary Table 8 ).
These analyses predict that most CPDs could be rescued by one large-effect compensatory substitution. We tested this prediction experimentally. We posited that each vertebrate sequence that includes a CPD should also include its cis-compensatory allele. Therefore, every amino acid difference between the human sequence and the sequence of the orthologue(s) containing a CPD is a candidate compensatory substitution. Given the practical constraints of examining all possible compensatory substitutions in macromolecular complexes, we focused on substitutions within the same gene as the CPD.
Scanning our list of candidate CPDs, we noted two alleles in genes involved in ciliopathies: a protein-encoding p.N165H change in BBS4 and a p.R937L variant in RPGRIP1L, which contribute pathogenic alleles to Bardet-Biedl syndrome and Meckel-Gruber syndrome, respectively 3, 4 . These alleles were prioritized because: (1) BardetBiedl and Meckel-Gruber syndromes have a severe effect on reproductive fitness; (2) previous studies have established loss-of-function zebrafish phenotypes rescuable by human messenger RNA for both genes 4, 25 ; (3) in vivo complementation has indicated both alleles to be deleterious to human protein function 4, 25 ; and (4) we observed multiple species with the human mutant allele fixed: six species for BBS4 165H and four for RPGRIP1L 937L (Fig. 3a, b) -for this reason, both alleles were predicted to be benign (PolyPhen-2, SIFT, MutationAssessor).
Comparative genomic analysis identified 9 candidate sites in BBS4 and 32 candidate sites in RPGRIP1L (Supplementary Table 9 ). To test each site, we took advantage of the established convergent extension defects induced by morpholino (MO)-mediated suppression of bbs4 or rpgrip1l in zebrafish 4, 25 . Consistent with previous observations, suppression of bbs4 or rpgrip1l induced convergent extension defects in 80% and 50% of embryos respectively (n 5 50-100 embryos; Fig. 3c-e) . Co-injection of MO with human wild-type mRNA rescued this phenotype, whereas injection with human mutant mRNA showed no improvement (Fig. 3d, e) . We next tested the entire candidate complementing allelic series for each gene. For BBS4, the introduction of 2/9 candidate residues in cis with the 165H-encoding mRNA ameliorated the phenotype in a manner indistinguishable from wild-type mRNA. Strikingly, both complementing alleles affected the same amino acid and were specific to the compensatory changes: the 165H/366N and the 165H/366S behaved as null, whereas 165H/ 366R was indistinguishable from wild type; 165H/366T converted the functional null to a hypomorph ( Fig. 3d and Extended Data Fig. 2a) .
We observed a similar pattern for RPGRIP1L. Testing each of the 32 candidate sites identified three complementing events, two of which map to the same region: 937L/189L, 937L/193L and 937L/961T (Fig. 3e and Extended Data Fig. 2b ). Testing each complementing allele individually showed them to be either extremely mild or benign (Supplementary Table 9 ). Finally, comparative genomic analysis showed that these data could explain the tolerance of the RPGRIP1L 937L change in all four species and of the BBS4 165H change in 4/6 species (Fig. 3a, b) .
The above analysis is limited by its retrospective nature. We therefore tested the usefulness of our model in ab initio gene discovery. We have recently initiated a whole-exome sequencing (WES) and func- Table 9 for embryo counts. We enrolled a 17-month-old female with an undiagnosed neuroanatomical condition hallmarked by microcephaly (Fig. 4a) . We filtered WES data for non-synonymous and splice variants with a minor allele frequency of ,1%, and we conducted a proband-centric trio analysis that yielded four candidates: de novo missense changes in BTG2 and NOS2; and recessive missense variants in TTN and LAMA1. Testing of an unaffected sibling excluded LAMA1; TTN, a known dominant cardiomyopathy locus 27 , is an unlikely driver. To investigate the pathogenicity of the BTG2 (p.V141M) and NOS2 (p.P795A) protein-encoding changes, we studied btg2 and nos2 in zebrafish. Reciprocal use of Basic Local Alignment Search Tool (BLAST) between Homo sapiens and Danio rerio identified a single zebrafish btg2 orthologue and two zebrafish nos2 orthologues. We injected splice-blocking MO (sb-MO) or translational-blocking MO (tb-MO) (Extended Data Fig. 3 ) into zebrafish embryos (3 ng; n 5 80 embryos per injection) and scored for head size defects at 4 days postfertilization (dpf) by measuring the anterior-posterior distance between the forebrain and the hindbrain (Fig. 4b) . For nos2a/b MOinjected embryos, we saw no differences at the highest dose injected (8 ng for nos2a/b sb-MOs; Supplementary Table 10) . By contrast, we found a significant reduction of anterior structures in btg2 morphants (P , 0.0001; Fig. 4b, c) . Co-injection of wild-type human BTG2 mRNA with tb-MO resulted in significant rescue (P , 0.0001; Fig. 4c ). In contrast, injection of mRNA harbouring 141M was significantly worse at rescue than wild type (P , 0.0001; Fig. 4c ).
BTG2 is a regulator of cell cycle checkpoint in neuronal cells 28 and is strikingly intolerant to variation in humans (Exome Variant Server (EVS)). To test the pathogenicity of 141M by a different assay, we performed antibody staining at 2 dpf (a time before the manifestation of microcephaly). We marked post-mitotic neurons in the forebrain with antibodies against neuronal HuC/HuD antigens, and we scored (blind, triplicate) on the basis of an established paradigm 29 . btg2 morphants displayed a significant decrease in HuC/HuD staining (P , 0.0001; Extended Data Fig. 4 ). This defect was rescued with wild-type BTG2 mRNA (P , 0.05), but could not be ameliorated by 141M-encoded mRNA co-injection (Extended Data Fig. 4) . Importantly, co-injection of btg2 tb-MO with two rare control EVS alleles (p.A126S and p.R145Q) resulted in rescue, providing evidence for assay specificity (Extended Data Fig. 4b) . As a third test, we stained whole embryos with a phospho-histone H3 (PH3) antibody that marks proliferating cells. We counted the number of positive cells in a defined anterior region of embryos. We saw a significant reduction in cell proliferation in the heads of 2 dpf btg2 morphants (P , 0.0001); this defect was likewise rescued by co-injection of wild-type mRNA, while 141M mutant rescue was indistinguishable from btg2 tb-MO alone (P 5 0.38; Fig. 4b, d) . Combined, all three assays indicated that BTG2 p.V141M is pathogenic and that haploinsufficiency of this gene probably contributes to the microcephaly of the proband.
Despite our functional and genetic data for p.V141M, this allele was predicted computationally to be benign. A likely reason is that, with the exception of primates, most BTG2 orthologues encode Met at the orthologous position (Fig. 4f) . These data suggested that V141 might represent a CPD site in primates that branched from the ancestral methionine. To test this possibility, we identified nine BTG2 sites that co-evolved with 141M (Supplementary Table 11 ), which we mutagenized into the human construct encoding 141M. We then injected embryos with btg2 MO; MO plus wild-type human BTG2 mRNA; MO plus 141M-encoding mRNA; or MO plus 141M in cis with one of the nine candidate complementing alleles. Seven of the alleles had no effect (Supplementary Table 11 ). However, R80K-or L128V-encoded mRNA on the 141M backbone rescued the number of PH3-positive cells to wild-type levels ( Fig. 4e and Extended Data  Fig. 2c) ; both alleles were benign on their own (Supplementary  Table 11 ). Taken together, our data indicated that 141M is deleterious in the human background, but the protection of this residue conferred by either Lys 80 or by Val 128 can explain .90% (54/59) of species encoding 141M (Fig. 4f) .
To improve the scalability of detecting CPDs, we used our model of CPD evolution to develop a computational predictor for distinguish- Table 10; white arrows in b), a.u., arbitrary units. d, 2 dpf zebrafish embryos stained for PH3. Human RNA containing the V141M mutation is unable to rescue the reduced proliferation of btg2 morphants. Scale bars, 250 mm. e, Quantification of PH3-positive cells: human RNA with mutations V141M and either R80K or L128V can rescue knockdown of btg2. Error bars represent standard deviation. f, The 141M allele is fixed in 59/87 species besides primates, examples displayed here. See Supplementary Table 11 for PH3 quantification. 
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ing variants that are unlikely to be CPDs from those that might be CPDs, and to identify candidate compensations to aid experimental design (http://genetics.bwh.harvard.edu/cpd/). Initial testing of this tool intimated high negative predictive values but modest positive predictive values, probably due to the dearth of known CPDs (Supplementary Note).
Our results contrast with some previous studies that claim that epistasis is ubiquitous 7, 10 ; or that it is practically nonexistent 9 ; or that it is commonly of higher order 12, 13 . The most likely explanation for this discrepancy is that such studies have examined different kinds of variation and traits. For example, studies on the evolution of genetic incompatibilities rely on assumptions of high mutation rate and weak negative selection, assumptions that generally do not hold for the case of pathogenic missense variation 10, 30 . The difference with the studies suggesting higher-order cis-interactions may be to do with the scale of evolutionary time our analyses probe: the span of hundreds of millions of years of evolution represented by the vertebrate alignment may not be long enough to reveal higher-order combinations of non-synonymous SNVs. Indeed, using neutral SNVs from the HumVar data set as a control, we estimate the vertebrate alignment has explored 12% of pairwise interactions between SNVs, compared to 0.6% of three-way interactions between SNVs. It is possible that higher-order interactions are common, but are not detectable without a deeper alignment.
Finally, considering the accelerated use of genome editing to model human pathogenic mutations in a variety of model organisms, our data highlight the critical need to not only pair computational predictions with functional studies, but also to evaluate the effect of human mutations in the context of the human sequence.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
METHODS
Data sets of known benign and pathogenic variants. Our primary training data set was HumVar, one of the training data sets for PolyPhen-2.2.3. We used the most recent public release at the time of this publication (December 2011), available for download at http://genetics.bwh.harvard.edu/pph2/dokuwiki/downloads. This data set is derived from SwissVar variant annotations 19 . It contains 22,207 variants annotated as pathogenic and 21,433 variants annotated as benign. We also used a data set of pathogenic variants derived from the June 2014 release of the ClinVar database 20 . This data set consists of all missense variants from ClinVar that are unambiguously (that is, classified the same by all submitters) and confidently (that is, not a 'Likely' annotation) annotated as 'Pathogenic'. It contains 10,596 variants annotated as pathogenic and 1,926 variants annotated as benign. The intersection of these two data sets contains 3,563 variants annotated as pathogenic and 454 variants annotated as benign. As an additional control, we required that the pathogenic variants be absent from 6,503 human exomes 31 (EVS; http:// evs.gs.washington.edu/EVS/). This most stringent data set contains 3,062 variants annotated as pathogenic. Comparative genomics screen for CPDs. We used the University of California, Santa Cruz (UCSC) MultiZ whole-genome alignments of 100 vertebrate sequences 32 , downloaded from UCSC as translated exons. As an alternative alignment strategy, we used the EPO alignment of 37 eutherian mammal species 33 , downloaded as nucleotide sequences and translated for all aligned species using the human open reading frame. In cases in which the alignment contained multiple sequences from the same species, only the sequence most similar to the human sequence was retained. Variants were classified as CPDs if the variant amino acid was found in the translated sequence of any vertebrate orthologue other than human or chimpanzee, with chimpanzee being excluded because presence in the chimpanzee sequence may be used as evidence for neutrality in variant annotation databases. The resulting data set of neutral and deleterious variants found in vertebrate orthologues is available (see Source Data for Fig. 1 ). Statistical models of variant density. We modelled the density of benign variants with an exponential distribution, with scale parameter b neut representing the mean time to fixation of neutral alleles. We used three different models for the density of CPDs. (1) k compensatory changes fix at rate 1/h, followed by the now-neutral CPD at the same rate. This is represented by a gamma distribution with shape parameter k 1 1 and scale parameter h. (2) k compensatory changes fix at rate 1/h 1 , followed by the now-neutral CPD at an independent rate 1/h 2 . This is represented by the convolution of a gamma distribution with shape parameter k and scale parameter h 1 , and an exponential distribution with scale parameter h 2 . (3) k compensatory changes fix at rate 1/b comp , followed by the now-neutral CPD at the neutral rate 1/b neut .
We assume a reversible model of evolution, so that the same three models can apply both to the fixation of CPDs not present in an ancestral sequence and to the loss of CPDs that are present in an ancestral sequence. The random variable used in these models is the sequence distance to the closest sequence containing the variant, where sequence distance is defined as the fraction of aligned (that is, nongapped) positions that are identical. Fitting observed density to statistical models. We recorded for each variant found in a vertebrate orthologue the minimum number of amino acid differences between that variant and a vertebrate orthologue, not counting gapped sites, normalized by the length of the sequence. We then used maximum likelihood to fit the neutral model and each of the three pathogenic models described earlier, using the Broyden-Fletcher-Goldfarb-Shanno (BFGS) optimization algorithm to maximize the likelihood functions. We repeated the fit using each of our filtered variant data sets and alignment methodologies, as well as discarding all variants that were only found in the alignment in a single sequence. All three models fit reasonably well, and all produced qualitatively similar results on all data sets and alignment methodologies. The exact fitted parameter values are found in Supplementary Table 8 . Prediction method. Our prediction method is implemented in Perl, and the source code is available (Supplementary Data 1-CPD Predictor Code). To calculate the probability that a variant is a CPD, we find the minimum distance to the variant in the multiple sequence alignment and apply Bayes' Law. We use the third likelihood model described earlier, where the CPD fixes at the neutral rate, using the maximum likelihood inferred parameter values. As our prior we use the well-established result that 10% of variants seen in another sequence are CPDs. Candidate compensation sites are identified by collecting all substitutions found in any sequence containing the candidate CPD, prioritizing sites that are substituted in many sequences over sites that are substituted in only a few sequences. WES. Research study participants were enrolled upon informed consent according to protocols approved by the Duke University Internal Review Board. We conducted paired-end pre-capture library preparation by fragmenting genomic DNA through sonication, ligating it to the Illumina multiplexing PE adapters, and PCR amplification using indexing primers. For target enrichment/exome capture we enriched the pre-capture library by hybridizing to biotin-labelled VCRome 2.1 (ref. 34) in-solution Exome Probes at 47 uC for 64-72 h. For massively parallel sequencing, the post-capture library DNA was subjected to sequence analysis on an Illumina Hiseq platform for 100 bp paired-end reads (1303 median coverage, .95% target coverage at 103). Primary data were interpreted and analysed by Mercury 1.0; the output data from Illumina HiSeq were converted from bcl files to FastQ files by Illumina CASAVA 1.8 software, and mapped by the BWA program. We performed variant calls using Atlas-SNP and Atlas-indel 35 . Morpholino design. MOs targeting zebrafish bbs4 and rpgrip1l were obtained from Gene Tools, and described previously 4, 25 . MOs against zebrafish btg2 and nos2 were obtained from Gene Tools (Extended Data Fig. 3 ; sequences available upon request). Site-directed mutagenesis. Mutant alleles were generated as described 25 . Sequences were validated via Sanger sequencing on Applied Biosystems 3730xl DNA Analyzer. mRNA synthesis and zebrafish embryo injection. mRNA was transcribed in vitro as described 36 using SP6 Message Machine kit (Ambion). MO and mRNA concentrations were determined based on the combination by which wild-type mRNA efficiently rescued the morphant phenotype. The same concentrations were used for rescue with mutant mRNA or injection of mRNA alone. The MO and mRNA concentrations injected were as follows: 0.7 ng bbs4 MO and 100 pg BBS4 mRNA; 5 ng rpgrip1l MO and 100 pg RPGRIP1L mRNA; 3 ng btg2 MO and 150 pg BTG2 mRNA; 8 ng nos2a; 8 ng nos2b. All animal work was performed in accordance with the protocols and guidelines of the Duke Institutional Animal Care and Use Committee. Classification and scoring of embryos. Embryos injected with bbs4 or rpgrip1l MOs were classified into two graded phenotypes on the basis of the relative severity compared with age-matched uninjected controls from the same clutch, as described previously 25 . Comparisons between injections of MO alone, mRNA alone, mutant rescue, and wild-type rescue were performed by x 2 test. Embryos injected with btg2 MO at were fixed in 4% paraformaldehyde at either 2 dpf or 4 dpf. Two days post-fertilization embryos were stained for HuC/HuD or PH3. HuC/HuD was scored and quantified as described 25 . Four days post-fertilization embryos were transferred to 13 PBS and bright-field dorsal images were captured; we assessed head size by measuring the distance from the anterior-most region of the forebrain to the hindbrain as defined by the attachment of the pectoral fins.
PH3-positive cell quantification was done using the Image-based Tool for Counting Nuclei (ITCN) plugin for the ImageJ software. Rolling background subtraction (25-pixel radius) and outlier removal (2.5-pixel radius, threshold 5 5) were used to process images. Linear measurement of a typical cell was used to determine cell radius for ITCN analysis. Threshold level was set to 0.5. Statistical comparisons between groups were performed with a Student's t-test. Figure 4 | HuC/HuD staining and quantification of 2 dpf zebrafish embryos confirms pathogenicity of BTG2 V141M. a, Suppression of btg2 leads to a decrease of HuC/HuD levels at 2 dpf. Representative ventral images of control, btg2 morphants (images show unilateral or absent HuC/ HuD expression), and a rescued embryo injected with a btg2 MO plus human BTG2 wild-type (WT) mRNA. Scale bar, 250 mm. b, Percentage of embryos with normal, bilateral HuC/HuD protein levels in the anterior forebrain or decreased/unilateral HuC/HuD protein levels in embryos injected with btg2 MOs alone or MOs plus human BTG2 wild-type or variant mRNAs (p.V141M, index case; p.A126S and p.R145Q, control alleles). *P , 0.05 (two-tailed t-test comparisons between MO-injected and rescued embryos; n 5 38-78 per injection batch).
Extended Data
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